Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 2;2(1):12.
doi: 10.1186/1756-6614-2-12.

The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report

Affiliations

The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report

Huy A Tran et al. Thyroid Res. .

Abstract

Background: Hepatitis C virus is a highly immunogenic pathogen often inducing autoimmune activation changes and this can often be further exacerbated by Interferon therapy. As HCV is lymphocytotropic, it can modulate T cell and B cell antibody responses, affecting many endocrine organs, most commonly the thyroid.

Case presentation: We hereby describe a case of fluctuating and wavering thyrotropin autoantibodies of both stimulating and blocking nature in the setting of Graves's ophthalmopathy, hepatitis C infection and interferon-alpha, causing hypo- and subsequently hyper-thyroidism. The autoantibody profile was clearly modified during interferon therapy and settled into a new equilibrium at the completion of treatment.

Conclusion: The case highlights the possible existence of a dual thyroid autoantibody population associated with hepatitis C, and its modulation by interferon therapy, which further compounds the difficulties in the assessment thyroid disease in this setting.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Magnetic Resonance Imaging of the orbits, showing congestion of the retro-orbital space and enlargement of the extraocular muscles (arrows), consistent with the diagnosis of Graves' Ophthalmopathy.
Figure 2
Figure 2
The immunomodulating effect of Interferon therapy on the TS and TB subsets of autoantibodies and its effects on thyroxine dosage and nuclear uptake patterns. Note: the graphs are only approximate representations, not to exact scale.

Similar articles

Cited by

References

    1. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly CJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–285. doi: 10.1530/EJE-07-0666. - DOI - PubMed
    1. Dienstag JL, McHutchinson JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterol. 2006;130:225–230. doi: 10.1053/j.gastro.2005.11.011. - DOI - PubMed
    1. Morgenthaler NG, Pampel I, Aust G, Seissler J, Scherbaum WA. Application of bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor. Horm Metab Res. 1998;30:162–168. doi: 10.1055/s-2007-978858. - DOI - PubMed
    1. Ajjan RA, Weetman AP. Techniques to quantify TSH receptor antibodies. Nature Clin Pract Endocrinol Metab. 2008;4:461–468. doi: 10.1038/ncpendmet0886. - DOI - PubMed
    1. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev. 1998;19:673–716. doi: 10.1210/er.19.6.673. - DOI - PubMed